Abstract
Purpose
The aim of this prospective cohort study was to evaluate the therapeutic target attainment
of 3-hour extended infusion of meropenem in patients with septic burns in the early
and late periods of septic shock.
Methods
Meropenem serum levels were determined by liquid chromatography from blood samples
collected within 48 hours (early period) of therapy and 10 to 14 days afterward (late
period). Pharmacokinetic properties were investigated by noncompartmental analysis,
and the therapeutic target was defined as 100% of the time above the MIC (100%fT> MIC).
Findings
Fifteen patients with 90 measured meropenem concentrations were included. Throughout
the entire course of antimicrobial therapy, the therapeutic target was attained against
gram-negative pathogens with an MIC ≤ 2 mg/L. Pathogens with intermediate susceptibility
to meropenem were only covered in the early phase of therapy.
Implications
Higher-dose regimens or continuous infusions may be necessary to guarantee antimicrobial
coverage of meropenem against less sensitive pathogens in patients with septic burns.
Key words
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical TherapeuticsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Sepsis in the burn patient: a different problem than sepsis in the general population.Burns Trauma. 2017; 5: 23
- Pharmacokinetics and Pharmacodynamics of Antimicrobial Agents in Burn Patients.Surg Infect (Larchmt). 2021; 22: 77-82
- Therapeutic drug monitoring of beta-lactam antibiotics in burns patients–a one-year prospective study.Ther Drug Monit. 2012; 34: 160-164
- Population pharmacokinetics of meropenem in burn patients.J Antimicrob Chemother. 2010; 65: 2428-2435
- Pharmacokinetics–pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients.Crit Care. 2018; 22: 233
- The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).JAMA. 2016; 315: 801-810
- Prediction of creatinine clearance from serum creatinine.Nephron. 1976; 16: 31-41
- Pharmacokinetic-pharmacodynamic correlation for meropenem applied to a burn child using a bioanalytical liquid chromatographic method.Braz J Pharma Sci. 2011; 3: 4-12
MERREM intravenous injection. Package insert. AstraZeneca Pharmaceuticals LP (per FDA), 1996. Accessed January 25, 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050706s037lbl.pdf
- Comparison of the pharmacodynamics of meropenem in healthy volunteers following administration by intermittent infusion or bolus injection.J Antimicrob Chemother. 2003; 52: 518-521
Clinical & Laboratory Standards Institute: CLSI Guidelines. Clinical & Laboratory Standards Institute. Accessed July 19, 2021. https://clsi.org/.
- Burn Wound Infections.Clin Microbiol Rev. 2006; 19: 403-434
- Does Beta-lactam pharmacokinetic variability in critically ill patients justify therapeutic drug monitoring? a systematic review.Ann Intensive Care. 2012; 2: 35
- Applying pharmacokinetic/pharmacodynamic principles in critically ill patients: optimizing efficacy and reducing resistance development.Semin Respir Crit Care Med. 2015; 36: 136-153
- Incidence and bacteriology of burn infections at a military burn center.Burns. 2010; 36: 461-468
- Pharmacokinetics of meropenem in burn patients with infections caused by Gram-negative bacteria: are we getting close to the right treatment?.J Glob Antimicrob Resist. 2020; 20: 22-27
- Common pathogens in burn wound and changes in their drug sensitivity.Burns. 2011; 37: 805-807
- Dosing regimen of meropenem for adults with severe burns: a population pharmacokinetic study with Monte Carlo simulations.J Antimicrob Chemother. 2015; 70: 882-890
Article info
Publication history
Published online: March 06, 2022
Accepted:
February 13,
2022
Footnotes
Accepted for publication February 13, 2022.
Identification
Copyright
© 2022 Elsevier Inc.
